Cytosorbents (NASDAQ:CTSO) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Shares of Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.04 and traded as high as $1.05. Cytosorbents shares last traded at $1.00, with a volume of 44,234 shares.

Analyst Upgrades and Downgrades

CTSO has been the topic of several analyst reports. HC Wainwright reissued a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Monday, January 13th. Finally, StockNews.com began coverage on shares of Cytosorbents in a research note on Wednesday. They set a "hold" rating for the company. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cytosorbents currently has an average rating of "Moderate Buy" and a consensus target price of $4.67.

Cytosorbents Price Performance

The company's 50 day moving average price is $0.95 and its 200 day moving average price is $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a market cap of $54.95 million, a price-to-earnings ratio of -2.79 and a beta of 0.58.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). The firm had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. During the same quarter last year, the firm earned ($0.21) earnings per share. On average, equities research analysts predict that Cytosorbents Co. will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently bought and sold shares of CTSO. Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Sargent Investment Group LLC lifted its position in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock worth $2,439,000 after buying an additional 192,747 shares in the last quarter. Finally, Atomi Financial Group Inc. acquired a new position in Cytosorbents during the 3rd quarter worth about $51,000. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.